4 days Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It’s Not For A GLP-1 Investor's Business Daily
Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.
The post Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 appeared first on Investor's Business Da…